The cash-pay question: how buyers are repricing ketamine practices

For years, a high cash-pay share was an unqualified selling point for ketamine practices: no prior authorizations, no recoupment risk, no payer negotiations. That view is becoming more nuanced.

Buyers now ask a harder question: how durable is the demand? A cash-pay practice with diversified referral sources and strong repeat-treatment patterns underwrites very differently from one dependent on paid search with rising cost per new patient. Two practices with identical revenue can price far apart on this distinction alone.

Marketing performance data — monthly lead volume, cost per acquisition, the organic-versus-paid split — has moved from 'nice to have' to a standard diligence request for cash-pay-heavy practices.

Limneo perspective: the listing wizard's optional marketing profile exists for exactly this reason. Sellers who fill it in give buyers the confidence to pay for cash-pay revenue rather than discount it.